Nov. 2 (Bloomberg) -- Mela Sciences Inc., the maker of the MelaFind melanoma-detection device, gained 19 percent after receiving Food and Drug Administration approval to sell the product in the U.S.
Mela rose to $6.42 at 8:10 a.m. The Irvington, New York-based company said in a statement today that it plans to first introduce the test in the northeastern U.S. in 2012.
To contact the reporter on this story: Bruce Rule in New York at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at Rgale5@bloomberg.net